{
    "ABLI.ST": {
        "short_name": "Abliva AB",
        "long_name": "Abliva AB (publ)",
        "summary": "Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "state": null,
        "city": "Lund",
        "zipcode": "223 81",
        "website": "http://abliva.com",
        "full_time_employees": 9
    },
    "L7R.F": {
        "short_name": "LIPIDOR AB",
        "long_name": "Lipidor AB (publ)",
        "summary": "Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, and AKP-03 AKP-07 for eczema. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, and acne and wart treatment. The company has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. Lipidor AB (publ) was founded in 2009 and is based in Stockholm, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "state": null,
        "city": "Stockholm",
        "zipcode": "106 91",
        "website": "http://lipidor.se",
        "full_time_employees": null
    },
    "LIPI.ST": {
        "short_name": "Lipidor AB",
        "long_name": "Lipidor AB (publ)",
        "summary": "Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, and AKP-03 AKP-07 for eczema. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, and acne and wart treatment. The company has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. Lipidor AB (publ) was founded in 2009 and is based in Stockholm, Sweden.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "STO",
        "market": "se_market",
        "country": "Sweden",
        "state": null,
        "city": "Stockholm",
        "zipcode": "106 91",
        "website": "http://lipidor.se",
        "full_time_employees": 1
    },
    "NEVPF": {
        "short_name": "ABLIVA AB",
        "long_name": "Abliva AB (publ)",
        "summary": "Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Sweden",
        "state": null,
        "city": "Lund",
        "zipcode": "223 81",
        "website": "http://abliva.com",
        "full_time_employees": 9
    },
    "NTP.F": {
        "short_name": "ABLIVA AB AK",
        "long_name": "Abliva AB (publ)",
        "summary": "Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Sweden",
        "state": null,
        "city": "Lund",
        "zipcode": "223 81",
        "website": "http://abliva.com",
        "full_time_employees": 9
    }
}